Germline testing: reading an inherited-risk result
In one sentence
Germline testing looks for constitutional genetic variants that may explain inherited susceptibility to cancer.
The intuition
Imagine comparing a family document with a reference edition. Finding a difference is the first step; deciding what it means is another. A missing finding also depends on which pages were inspected. The analogy stops there: real tests have technical limits, and variant interpretation requires biological and clinical evidence.
Constitutional means belonging to the person's genetic makeup, rather than being confined to the tumor. Some constitutional changes arise newly rather than being inherited from a parent. Germline versus somatic explains that origin distinction.
How it works
After consent and a review of personal and family history, a laboratory analyzes DNA, or deoxyribonucleic acid from a suitable non-tumor specimen. A panel examines multiple hereditary cancer genes; a targeted test may instead examine a known family variant. [1]
The laboratory then classifies variants using evidence such as population frequency, family segregation and functional studies. A classification can change as evidence accumulates. Detecting a sequence difference and interpreting its disease relevance are separate stages. [2]
| Result | What it establishes | What it leaves open |
|---|---|---|
| Pathogenic or likely pathogenic | A variant with sufficient evidence of a disease-associated effect in the stated context | Whether or when cancer will occur; the existing tumor's behavior |
| Variant of uncertain significance (VUS) | A detected change whose relevance remains uncertain | Whether it is harmful; it should not be used as a pathogenic result |
| True negative for a known family variant | The tested person did not inherit that particular variant, within a test able to detect it | Other risk factors or a separate genetic cause |
| Uninformative negative | No explanatory harmful variant was found, without a known family cause to exclude | An undetected or not-yet-understood inherited cause |
The last two rows explain why “negative” needs context. A negative panel can reduce some concerns while leaving family history relevant. It also does not mean a tumor has no acquired genetic changes. [1]
Why it matters in cancer
Germline results can inform questions about inherited susceptibility and relatives. Cascade testing means testing relatives for a confirmed family finding; each person's result still needs its own interpretation. [1]
A tumor-only result can raise a hereditary question, but does not replace germline testing. Conversely, a germline report does not measure tumor repair function or completely determine treatment selection. Counseling connects it to the person's history and question. The American Society of Clinical Oncology–Society of Surgical Oncology guideline separates pathogenic results from VUS findings and supports follow-up for reclassification. [3]
Assay card
| Field | What to ask |
|---|---|
| Measures | Presence of specified constitutional variants in the assay's covered regions |
| How | Collect specimen, analyze sequence and relevant variant types, classify and report |
| Input and tissue cost | Usually blood, saliva or cheek cells; consumes the submitted aliquot, without necessarily using tumor tissue |
| Output and units | Gene, reference sequence, variant name, classification and test limitations; not a universal “hereditary percentage” |
| Thresholds | Classification evidence and laboratory detection limits; no single positive cutoff shared by every method |
| Failure modes | Inadequate specimen, missed variant types or regions, uncertain interpretation, or an unsuitable specimen for the person's circumstances |
| Cannot tell you | Current tumor function, all familial risk, or whether a treatment will benefit an individual |
| Validation context | Check the clinical laboratory, covered variant classes and report version; laboratory quality does not make every detected variant clinically actionable |
The consent process also addresses privacy and implications for family members. A report can bring relief, uncertainty or both; its interpretation should explain those limits clearly. [1]
Common confusions
- A larger panel is not automatically a more informative answer. Additional genes can introduce uncertain findings. [1]
- A VUS is not “almost positive.” It is a separate evidence category; the guideline says it should not determine management. [2, 3]
- A true negative excludes a particular family variant. It does not eliminate every cause of cancer.
- An uninformative negative is not proof of a hidden mutation. It means the test did not establish an explanatory finding.
Try it
Fictional example: A family has a confirmed pathogenic BRCA1 variant. Lee's test explicitly covered that variant and did not detect it. Another family has several cancers but no known genetic cause; Morgan's panel finds no pathogenic variants. Are these equivalent negative results?
Answer: No. Lee has a true negative for the specified family variant. Morgan has an uninformative negative for the family's unexplained pattern. Neither statement means zero cancer risk.
Explain it back
What three details belong beside “negative”? One answer: the tested genes and variant types, whether a family variant was known, and the relevant personal and family history.
Takeaway
Read a germline result as a finding with a defined scope and classification, then ask what question it actually answers.
Related concepts
Sources
Source check: October 10, 2026. Examples are fictional; expert and learner review remain pending.
References
- NCI: genetic testing for inherited cancer risk — specimens, negative-result context, consent and counseling.
- Richards et al., 2015 (PMID 25741868) — American College of Medical Genetics and Genomics/Association for Molecular Pathology classification framework; abstract and relevant full-text interpretation passages checked.
- Bedrosian et al., 2024 (PMID 38175972) — ASCO–Society of Surgical Oncology guideline; abstract checked for counseling and VUS interpretation.